Julian Adams, retiring Gamida Cell CEO
September 19, 2022 11:07 AM EDTUpdated 11:21 AM
People

As Gami­da Cell eyes its first cell ther­a­py ap­proval, Ju­lian Adams is head­ing out

Amber Tong

Ju­lian Adams didn’t ex­act­ly fin­ish what he set out to do at Gami­da Cell, but it seems like he got close enough.

The sea­soned biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times